492 results about "Sarcoma" patented technology

An IL-6 production inhibitor which comprises a hydroxamic acid derivative of formula (I) (wherein all the symbols have the same meanings as defined in the specification), an equivalent thereof, a non-toxic salt thereof or a prodrug thereof as an active ingredient. Because of having an IL-6 production inhibitory activity, the compound of formula (I) may be useful for the prevention and / or treatment of various inflammatory diseases, sepsis, multiple myeloma, plasma cell leukemia, osteoporosis, cachexia, psoriasis, nephritis, renal cell carcinoma, Kaposi's sarcoma, rheumatoid arthritis, hypergammaglobulinemia (gammophathy), Castleman's disease, intra-atrial myxoma, diabetes, autoimmune disease, hepatitis, colitis, graft-versus-host disease, infectious diseases, endometriosis and solid cancer.

Methods are provided for diagnosing in a subject a condition, such as a carcinoma, sarcoma or leukemia, associated with hypermethylation of genes by isolating the genes from tissue containing as few as 50 to 1000 tumor cells. Using quantitative multiplex methylation specific PCR (QM-MSP), multiple genes can be quantitatively evaluated from samples usually yielding sufficient DNA for analyses of only 1 or 2 genes. DNA sequences isolated from the sample are simultaneously co-amplified in an initial multiplex round of PCR, and the methylation status of individual hypermethylation-prone gene promoter sequences is then determined separately or in multiplex using a real time PCR round that is methylation status-specific. Within genes of the panel, the level of promoter hypermethylation as well as the incidence of promoter hypermethylation can be determined and the level of genes in the panel can be scored cumulatively. The QM-MSP method is adaptable for high throughput automated technology.

Vector compositions comprising a myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted (MND) promoter operably linked to a chimeric antigen receptor (CAR) are provided.

The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).

The present invention discloses an anti-tumor compound and its preparation method,application, and pharmaceutical compositions. The anti-tumor compound is a 4 - nitro-substituted benzyl group ifosfamide ester prodrug thereof, or pharmaceuticallysalt, or solvate thereof of the structure of formula I. The structure of formula I. The present invention has the following advantage of being used for the treatment or prevention of mammalian tumor-related diseases, such as leukemia, hemangioma, glioma, Kaposi's sarcoma, ovarian cancer, breast cancer, lung cancer, pancreatic cancer, lymphoma, prostate, colon and skin tumors and their complications.

The invention belongs to the technical field of medicament, and particularly relates to preparation and application of phycocyanin extract. The phycocyanin extract is prepared by the following steps of: crushing spirulina cell walls of spirulina powder to obtain a crude extract by a repeated freeze-thawing method at the temperature of between 20 DEG C below zero and 4 DEG C; depositing the crude extract to obtain a crude protein extract by using 50 to 60 mass percent of ammonium sulfate; and then extracting and purifying the crude protein extract by adopting double aqueous phases, and removing salt by using excess infiltration to obtain phycocyanin extract solution. The phycocyanin extract mainly comprises phycocyanin, and the aqueous solution of the phycocyanin extract has the absorbance characteristics that A620 / 280 is slightly equal to 3.0+ / -0.2 and A620 / 650 is slightly equal to 2.2+ / -0.1. The phycocyanin extract is obtained by mainly combining the processes of ammonium sulfate deposition, double aqueous phase extraction, dialysis and salt removal and the like; and the phycocyanin extract administrated to S180 sarcoma mice with different dosages shows good tumor inhibiting effect and has no obvious toxicity on the spleen and the thymus gland.

A mathematical contouring algorithm that automatically determines the planning volume of a sarcoma prior to designing a brachytherapy treatment plan. The algorithm, utilizing computational geometry, numerical interpolation and artificial intelligence (AI) techniques, returns the planning volume in digitized and graphical forms in a matter of minutes. Such an automatic procedure reduces labor time and provides a consistent and objective method for determining planning volumes. In addition, a definitive representation of the planning volume allows for sophisticated brachytherapy treatment planning approaches to be applied when designing treatment plans, so as to maximize local tumor control and minimize normal tissue complications.

A mouse monoclonal antibody for antagonizing and inhibiting binding of a vascular endothelial cell growth factor (VEGF) and its receptor (VEGF-R), and a heavy chain variable region and light chain variable region amino acid sequence thereof. Also disclosed are a humanized preparation process of the antibody and a heavy chain variable region and light chain variable region amino acid sequence of the humanized antibody. The humanized antibody or its derivative can act as an ingredient of a pharmaceutical composition or be prepared into a suitable pharmaceutical preparation, is administered alone or in combination with a chemotherapy drug or other treatment means, and is used in broad-spectrum treatment of various solid tumors such as colon cancer, breast cancer and rhabdomyosarcoma.

The invention discloses a compound with protein kinase inhibiting activity as well as a preparation method and application of the compound. The compound has a structure shown as a formula I, a formula II and a formula III. The compound provided by the invention can be used for medicines for treating cancers related with kinase inhibition, such as acute and chronic leukemia, lymphoma, breast cancer, lung cancer and sarcoma, and diseases including acquired immunodeficiency syndrome and Alzheimer's disease and the like. The invention further discloses the preparation method of the compound with the protein kinase inhibiting activity; the compound is produced through solid fermentation on rice by utilizing actinomyces; a fermented product is extracted through ethyl acetate and then is subjected to silica-gel column chromatography, gel column chromatography and reversed-phase chromatography separation and purification to obtain a product; the preparation method is easy to operate and implement. (The formula I, the formula II and the formula III are shown in the description.).

A RNA nanoparticle is disclosed. According to base pairing rules, a particle is formed from a chain RNA, b chain RNA and c chain RNA, wherein sequence of the a chain RNA is SEQ ID No.1; sequence of the b chain RNA is SEQ ID No.2; and sequence of the c chain RNA is SEQ ID No.3. It shows through experimental verification at the cellular and animal level that the RNA nanoparticle provided by the invention has good biosecurity and excellent gene interference effect and specificity, can effectively inhibit growth of gastric cancer cell lines and transplant subcutaneous sarcoma and can be applied in prevention, cure and diagnosis of stomach cancer.

The invention discloses a long-chain recombination human bone pattern generating protein-2 and preparing method and application, which is characterized by the following: utilizing gene project technique to grow the protein in the expressing system of escherichia coli and bacillus subtilis; adopting human bone sarcoma cell mRNA to do reverse transcription to obtain the cDNA as form; augmenting nucleotide sequence of entire 114 amino acids naturally from carboxyl end; adding a segment of nucleotide in front of the first codon of primer 5' end; increasing a segment of polypeptide at N end corresponding to amino acid sequence; obtaining long-chain rhBMP-2 gene with molecular weight at 30KD and purity over 95%.

The present invention relates to minimally invasive X-ray guided interventions, in particular to an image processing and rendering system and a method for improving visibility and supporting automatic detection and tracking of interventional tools that are used in electrophysiological procedures. According to the invention, this is accomplished by calculating differences between 2D projected image data of a preoperatively acquired 3D voxel volume showing a specific anatomical region of interest or a pathological abnormality (e.g. an intracranial arterial stenosis, an aneurysm of a cerebral, pulmonary or coronary artery branch, a gastric carcinoma or sarcoma, etc.) in a tissue of a patient's body and intraoperatively recorded 2D fluoroscopic images showing the aforementioned objects in the interior of said patient's body, wherein said 3D voxel volume has been generated in the scope of a computed tomography, magnet resonance imaging or 3D rotational angiography based image acquisition procedure and said 2D fluoroscopic images have been co-registered with the 2D projected image data. After registration of the projected 3D data with each of said X-ray images, comparison of the 2D projected image data with the 2D fluoroscopic images—based on the resulting difference images—allows removing common patterns and thus enhancing the visibility of interventional instruments which are inserted into a pathological tissue region, a blood vessel segment or any other region of interest in the interior of the patient's body. Automatic image processing methods to detect and track those instruments are also made easier and more robust by this invention. Once the 2D-3D registration is completed for a given view, all the changes in the system geometry of an X-ray system used for generating said fluoroscopic images can be applied to a registration matrix. Hence, use of said method as claimed is not limited to the same X-ray view during the whole procedure.

Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein.

Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for an HLA-A11-restricted epitope of mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) (KRAS7-16), Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS), or Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS). Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

PCT No. PCT / US96 / 07370 Sec. 371 Date Nov. 28, 1997 Sec. 102(e) Date Nov. 28, 1997 PCT Filed May 22, 1996 PCT Pub. No. WO96 / 37625 PCT Pub. Date Nov. 28, 1996Recombinant avian sarcoma leukosis virus (ASLV)-derived retrovirus vectors having an expanded host range are described. The host range is expanded by the replacement of the ASLV envelope gene by an envelope gene from a virus capable of infecting both mammalian and avian cells. The resulting recombinant ASLV-derived retroviral vectors can replicate efficiently in avian cells, infect both avian and mammalian cells in high titer, and are replication-defective in mammalian cells. Thus, they are quite safe and advantageous for use in gene therapy and vaccines.

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

The present invention relates to novel biomarker for breast cancer, namely LSD1 and its application in inter alia the diagnosis of breast cancer. Furthermore, the present invention discloses a method of determining the LSD1 protein amount and the effect of LSD1 inhibitors on cancer cells selected from breast cancer, lung carcinoma and sarcoma.

The invention relates to the field of medicines, specifically to an integrin blocker which inhibits generation of tumor vasculature and has integrin endophilicity and binding capacity. The blocker is a polypeptide. The integrin blocker polypeptide can be used to treat solid tumor. The integrin blocker can be applied in the preparation of medicines for treating tumor. The sequence of the integrin blocker is Ala-Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys-Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro (the sequence contains two disulfide bonds and the pairing manner is 1-4 and 2-3). The invention is characterized in that the tumor origins from primary or secondary cancer and sarcoma of human head and neck, brain, thyroid, pancreas, lung, liver, oesophagus, stomach, mammary gland, kidney, gallbladder, colon or rectum, ovary, uterus, cervix, prostate, bladder and testis. According to the invention, treatment spectrum of the integrin blocker is greatly expanded, novel thinking and prospect are provided for drug development, and the integrin blocker polypeptide AP25 has substantial social value and market value.

Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II):wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.

Methods and formulations for treating a sarcoma in humans using an epimetabolic shifter, such as Coenzyme Q10, a building block of CoQ10, a derivative of CoQ10, an analog of CoQ10, a metabolite of CoQ10, or an intermediate of the coenzyme biosynthesis pathway, are described. Methods for assessing the efficacy of treatment of, diagnosing, and prognosing sarcoma are also provided.

Compounds, compositions and methods relating to EWS-FLI1 protein inhibitors are provided. The compounds have utility in the treatment of cancers including the Ewing's sarcoma family of tumors.

Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein.

Poly(ester-anhydrides) or polyesters formed from ricinoleic acid and natural fatty diacids and their method of preparation and its use for delivering bioactive agents including small drug molecules, peptides and proteins, DNA and DNA complexes with cationic lipids or polymers or nano and microparticles loaded with bioactive agents are disclosed herein. The drug delivery compositions are administered to a patient in a liquid form, increase in viscosity in vivo to form a drug depot or implant, and are able to release the incorporated bioactive agent for weeks. In the preferred embodiment, the drug delivery formulations are administered by injection. In one embodiment, the compositions are suitable for local or regional delivery of drugs to diseased sites, such as treating solid tumors and bone infections. In a preferred embodiment, the drug delivery compositions are suitable for site-specific chemotherapy for the treatment of solid tumors including: squamous cell carcinoma (SCC) of the head and neck, prostate cancer, and sarcomas for intratumoral injection or insertion.

The invention provides the application of tetracyclic triterpenoids compound cucurbitacins E in preparing anti-angiogenic drugs. The cucurbitacins E can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissue angiogenesis, hemangioma, Kaposi' s sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget' s disease angiogenesis. The invention also provides the application of a compound containing effective dose of cucurbitacins E and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.

The invention relates to a medicament composition containing tetrandrine, tetrandrine derivatives and a histone deacetylase (HDAC) inhibitor and application thereof in preparing medicaments for treating colon cancer, liver cancer, lung cancer, stomach cancer, encephaloma, sarcoma, pancreatic cancer, ovarian cancer, breast cancer, prostatic cancer or glioma. The medicament composition has remarkable synergistic effect, improves the curative effect of the medicament, decreases the administration dosage and reduces the occurrence of side effects.